Treatment planning for immunotherapy based treatments using non-thermal ablation techniques
Described herein are methods of performing immunotherapy on a subject and/or determining if a subject will be responsive to ablation immunotherapy.
1. A method of treating a tissue in a subject comprising:
ablating the tissue using a non-thermal ablation technique;
measuring a change in a treatment parameter during the step of ablating; and
administering an additional treatment to the subject in response to the measured change in the treatment parameter, wherein the additional treatment comprises is measuring the amount of a pro-inflammatory immune molecule or cell, a suppressive immune molecule or cell, or both in a bodily fluid or a biopsied tissue of the subject.
2. The method of claim 1 , wherein the step of administering the additional treatment occurs 4-30 days after the ablating.
3. The method of claim 1 , wherein the additional treatment further comprises a treatment selected from the group consisting of: tissue resection, thermal ablation, non-thermal ablation, chemotherapy, radiation therapy, immunotherapy, biologic therapy, genetic therapy, and combinations thereof.
4. The method of claim 1 , where the non-thermal ablation technique is irreversible electroporation.
5. The method of claim 4 , wherein the non-thermal ablation technique, is high-frequency irreversible electroporation.
6. The method of claim 1 , wherein the treatment parameter is bulk tissue conductivity.
7. The method of claim 6 , wherein the change in bulk tissue conductivity is measured by measuring current during the step of ablating.
8. The method of claim 1 , wherein the treatment parameter is measured by measuring current during the step of ablating.
9. A method of treating a tissue in a subject comprising:
ablating the tissue using a non-thermal ablation technique;
measuring a change in a treatment parameter during the step of ablating; and
administering an additional treatment to the subject in response to the measured change in the treatment parameter;
wherein the treatment parameter is measured by measuring current during the ablating; and
wherein the administering of the additional treatment occurs 4 to 30 days after the ablating when the current measured is between 25 A and 100 A.
10. The method of claim 9 , wherein the additional treatment is selected from the group consisting of: tissue resection, thermal ablation, non-thermal ablation, chemotherapy, radiation therapy, immunotherapy, biologic therapy, genetic therapy, and combinations thereof.
11. The method of claim 9 , wherein the additional treatment is measuring the amount of a pro-inflammatory immune molecule or cell, a suppressive immune molecule or cell, or both in a bodily fluid or a biopsied tissue of the subject.
12. The method of claim 9 , wherein the non-thermal ablation technique is configured to cause non-thermal irreversible electroporation of the tissue.
13. The method of claim 9 , wherein the treatment parameter is bulk tissue conductivity.
14. The method of claim 9 , wherein the step of administering occurs 0 to 5 days after the non-thermal ablation technique when the current is less than 25 A.
15. A method of treating a tissue in a subject comprising:
applying a plurality of electrical pulses to tissue of a subject, wherein the electrical pulses are configured to cause non-thermal ablation of the tissue;
measuring a current of the applied plurality of electrical pulses;
administering an additional treatment to the subject in response to and based on the measured current, wherein the step of administering occurs 0 to 5 days after the non-thermal ablation when the current is less than 25 A; and
wherein the step of administering occurs 4-30 days after the non-thermal ablation when the current is between 25 A and 100 A.
16. The method of claim 15 , wherein the additional treatment is selected from the group consisting of: tissue resection, thermal ablation, non-thermal ablation, chemotherapy, radiation therapy, immunotherapy, biologic therapy, genetic therapy, and combinations thereof.
17. The method of claim 15 , wherein the additional treatment is measuring the amount of a pro-inflammatory immune molecule or cell, a suppressive immune molecule or cell, or both in a bodily fluid or a biopsied tissue of the patient.
18. The method of claim 15 , wherein the plurality of electrical pulses are configured to cause non-thermal irreversible electroporation of the tissue.
19. The method of claim 15 , wherein in the plurality of electrical pulses are applied through a plurality of electrodes inserted into the tissue.